The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

NCT01836523 on ClinicalTrials.gov · last registry update 2017-03-06

An unusually large phase 3: 1,398 participants, more than double the 424 typical for the stage. The sponsor logged completion for June 2015. Primary outcome, as filed: Change From Baseline in HbA1c (Glycosylated Haemoglobin). liraglutide is approved in the US, but not for diabetes and type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 1,398
Started: 2013-11
Primary completion: 2015-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in HbA1c (Glycosylated Haemoglobin)

Conditions studied

Diabetes · Diabetes Mellitus, Type 1

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.